Please assess the completion status of the following clinical trial:

Trial Title: 5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with chronic lymphocytic leukemia (CLL), prolymphocytic leukemia, Richter's transformation or T-PLL who have previously been treated with fludarabine or another regime are eligible.~2. Patients with histologically or cytologically confirmed Richter's transformation.~3. Serum glutamic-oxaloacetic transaminase (SGOT) or serum glutamic-pyruvic transaminase (SGPT) less than x 2 normal levels.~4. Women of childbearing potential who have a negative pregnancy test prior to azacytidine treatment.~5. Women of childbearing potential who agreed not to become pregnant and men agreed not to father a child while on azacytidine treatment.~6. Performance 0-2 (ECOG). Adequate liver function (bilirubin of less than2mg/dl) and renal function (creatinine less than 2mg/dl). Adequate cardiac functions (NYHA cardiac III-IV excluded).~7. Signed informed consent.~Exclusion Criteria:~1. Breast feeding or pregnant females. Patients of (male and female) childbearing potential should practice effective methods of contraception; otherwise, they will be excluded. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.~2. Known or suspected hypersensitivity to azacytidine or Mannitol.~3. Active and uncontrolled infections.~4. Patients with advanced malignant hepatic tumors.~5. Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 5-Azacytidine (Type: EXPERIMENTAL): 5-Azacytidine 75mg/m\^2 subcutaneously daily for seven days. Treatment cycles will be repeated every 3-8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).